Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

Blueprint Medicines Corporation (BPMC) reported second-quarter 2024 adjusted loss of 80 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.28. The company had reported a loss of $2.19 per share in the year-ago quarter. Quarterly revenues of $138.2 million surpassed the Zacks Consensus Estimate of $105 million. Total revenues jumped almost 140% year over year. Despite the better-than-expected results, shares of Blueprint Medicines were down 7.4% on Aug 1 following the earnings announ ...